LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.96 -0.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.85

Max

3.99

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-12M -27M
Pardavimai	-5.3M 663K
P/E Sektoriaus vid.	22.5 49.8
Pelno marža	-3,998.492
Darbuotojai	69
EBITDA	-13M -27M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+243.47% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-234M 910M
Ankstesnė atidarymo kaina	4.46
Ankstesnė uždarymo kaina	3.96

Naujienos nuotaikos

By Acuity

29%

71%

86 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

0.7658 / N/A Palaikymas ir pasipriešinimas

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-08 23:55; UTC

Uždarbis

Review & Preview: Still Going Strong -- Barrons.com

2026-05-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 20:49; UTC

Uždarbis

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026-05-08 20:25; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Net $115M

2026-05-08 19:20; UTC

Rinkos pokalbiai

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026-05-08 19:18; UTC

Uždarbis

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026-05-08 19:16; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:08; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:05; UTC

Uždarbis

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026-05-08 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026-05-08 18:51; UTC

Uždarbis

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026-05-08 18:49; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 18:41; UTC

Uždarbis

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026-05-08 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026-05-08 17:14; UTC

Uždarbis

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026-05-08 17:04; UTC

Rinkos pokalbiai

Zcash Caps Off Parabolic Week -- Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-08 15:39; UTC

Rinkos pokalbiai

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

2026-05-08 15:39; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-08 15:39; UTC

Rinkos pokalbiai

Canada's Job Market Sees Worst Start in Years -- Market Talk

2026-05-08 15:36; UTC

Rinkos pokalbiai

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

2026-05-08 15:20; UTC

Rinkos pokalbiai

'Altcoin Season' Indicator on the Rise -- Market Talk

2026-05-08 15:20; UTC

Rinkos pokalbiai

Uždarbis

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

2026-05-08 15:05; UTC

Rinkos pokalbiai

Bitcoin Slips Back Below the $80k Mark -- Market Talk

2026-05-08 14:42; UTC

Rinkos pokalbiai

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

2026-05-08 14:39; UTC

Rinkos pokalbiai

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

243.47% į viršų

12 mėnesių prognozė

Vidutinis 13.67 USD 243.47%

Aukščiausias 17 USD

Žemiausias 11 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

86 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.